FDA Approves Mounjaro for Cardiovascular Risk Reduction in Type 2 Diabetes

The U.S. Food and Drug Administration (FDA) has granted approval for Mounjaro (tirzepatide), a medication designed to lower the risk of major cardiovascular events in individuals with type 2 diabetes who are at heightened risk. This significant decision, announced by Eli Lilly on August 28, marks an important advancement in diabetes care, particularly for patients facing cardiovascular challenges.

Mounjaro is now indicated for the reduction of major adverse cardiovascular events (MACE), which include non-fatal heart attacks, non-fatal strokes, and cardiovascular fatalities. Heart disease remains the leading cause of death for individuals with type 2 diabetes, making this approval a vital development in enhancing patient health outcomes. Kenneth Custer, PhD, executive vice president of Lilly Cardiometabolic Health, expressed that this new indication provides a proven strategy for reducing cardiovascular risks while also supporting blood sugar management and weight control.

The FDA’s endorsement is grounded in the findings from the SURPASS-CVOT trial, which was the first of its kind to directly compare two GLP-1 medications in a clinical setting, rather than against a placebo. This extensive study involved over 13,000 participants across 30 countries and followed them for a median duration of four years. Results indicated that Mounjaro demonstrated noninferiority to Trulicity (dulaglutide), another well-established GLP-1 medication with known cardiovascular benefits. Specifically, major cardiovascular events occurred in 12.2% of those taking Mounjaro, compared to 13.1% of participants on Trulicity, indicating an 8% lower relative risk for those on Mounjaro.

Dr. Mir Ali, medical director at MemorialCare Surgical Weight Loss Center, highlighted the significance of these findings, noting that Mounjaro may provide additional health advantages beyond its established roles in diabetes management and weight loss. The medication’s ability to support heart health is attributed to its multifaceted effects, including regulation of blood sugar levels, reduction of blood pressure, promotion of weight loss, improvement of cholesterol levels, and minimization of inflammation.

Dr. Randy Gould, a cardiologist, elaborated on how Mounjaro functions, explaining that it is a dual receptor agonist for glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). This dual action helps to lower blood sugar by enhancing metabolic processing and decreasing fat accumulation in the liver, while also stabilizing arterial plaques through reduced inflammation and endothelial dysfunction.

While the approval provides a promising new option for managing type 2 diabetes and associated cardiovascular risks, experts caution that the population studied consisted of individuals with existing cardiovascular conditions. Dr. Rigved Tadwalkar emphasized the need for caution in applying these findings to all patients taking tirzepatide.

Overall, the FDA’s approval of Mounjaro represents a significant step forward in the treatment landscape for type 2 diabetes, offering healthcare providers a new tool to combat both diabetes and cardiovascular disease.